CA
NZ
UK
AU
IND
US
MediWound Ltd. (NASDAQ: MDWD) identifies HOLD Alapkezelo Zrt. As the beneficial owner of 1,348,323 common shares, representing approximately 10.4% of the company’s common stock. The position is covered by an amended Schedule 13G/A dated August 27.
Cardiff Oncology, Inc. (NASDAQ: CRDF) will ask shareholders on October 22, 2026, to approve an amendment increasing authorized capital stock from 170,000,000 to 320,000,000 shares. The same measure would increase authorized common stock from 150,000,000 to 300,000,000 shares. A second proposal would allow the …
CITIUS ONCOLOGY, INC. (NASDAQ: CTOR) will hold its annual stockholder meeting on September 29, with three Class II director seats up for election.
Alto Neuroscience, Inc. (NYSE: ANRO) promoted Chief Financial Officer and ChiefBusinessOfficer Nicholas C. Smith to President and Chief Financial Officer effective August 26, 2026. The promotion makes Smith eligible for a $6,000,000 retention payment, while Amit Etkin continues as Chief Executive Officer.
Availability is expected in U.S. pharmacies, hospitals and clinics in the coming days.
Candor Therapeutics Inc. is pursuing a $750,000 exempt securities offering under a Simple Agreement for Future Equity, with $50,000 sold so far. Investors can see that $700,000 of the stated offering amount remains available, providing the clearest disclosed measure of the financing still to …
Xtant Medical Holdings (NYSE American:XTNT), a maker of orthobiologics and spinal-implant systems, rose even as a closer look at its latest results shows a company in transition, with revenue falling, a swing to a net loss and a lowered outlook. For investors weighing whether …
Stereotaxis (NYSE American:STXS), a developer of robotic systems for minimally invasive cardiac procedures, gained on the back of a key commercial inflection: revenue from its newly cleared robotic catheter has begun to ramp, and it recorded the first U.S. sale of its next-generation robotic …
Microbot Medical (NASDAQ:MBOT), a developer of surgical-robotics technology, slipped after achieving a pivotal milestone: FDA clearance and the commercial rollout of its LIBERTY endovascular robotic system. For investors, the transition from a development-stage company to an early commercial-stage one is reason for a fresh …
Adagio Medical Holdings (NASDAQ:ADGM), a developer of catheter-based devices for treating dangerous heart-rhythm disorders, slipped despite strong clinical results and a pending FDA submission. For investors, the question is whether the strong data can eventually offset the company's pre-revenue status and thin cash position.
Please wait processing your request...